McKinney, TX – October 21, 2013 – Erchonia
, the global leader in low level laser healthcare applications, today announces the company has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) to market its new XLR8 Laser for pain treatment.
Depending on the settings selected, the Erchonia XLR8 laser
can provide temporary relief of chronic neck and shoulder pain; reduce pain after liposuction of the thighs, hips and stomach; or reduce post-surgery pain after breast augmentation.
The Erchonia XLR8 laser
is a handheld device that uses low level laser technology to speed the recovery process following liposuction and breast augmentation by encouraging cell regeneration. The XLR8 laser is a noninvasive, safe way to manage pain—without negative side effects.
Steven Shanks, president of Erchonia comments, “The Erchonia XLR8 laser combines three FDA 510(k) market clearances into one device. With user-definable channels, an easy-to-use interface, and preset protocols, cold laser technology
is now more flexible than ever before.”
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit www.erchonia.com